LABORATORY NEWS
-
Quest Diagnostics To Offer FDA-Cleared Fujirebio Blood Test For Alzheimer's Disease
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.
- Claret Bioscience And Hamilton Company Partner To Automate NGS Library Prep Workflows
- Volition Announces Groundbreaking Lateral Flow Test For Point-Of-Care Quantification Of Nucleosomes
- AgileBio Brings Back Dymo–LabCollector Integration In Partnership With GA International
- Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition And Platform Rollout
ARCHIVED NEWSLETTER
- 07.08.25 -- Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet
- 06.24.25 -- Cleaning Process Capability: Understanding Populations, Samples, And Sample Size Requirements
- 06.10.25 -- AI's Potential To Aid Multispecific Analytical Characterization
- 05.27.25 -- Proper Care And Handling Of Coupons Used For Swab And Rinse Recovery Studies For Total Organic Carbon Analysis
- 05.13.25 -- ICH Revises Q1 Guideline, Advancing Stability Testing Standards